These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 38174337)

  • 1. Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases.
    Chen W; Zheng L; Wang J; Lin Y; Zhou T
    Front Endocrinol (Lausanne); 2023; 14():1320603. PubMed ID: 38174337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
    Haller H
    Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
    Wish JB; Pergola P
    Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiorenal benefits of finerenone: protecting kidney and heart.
    González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
    Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
    Pitt B; Agarwal R; Anker SD; Ruilope LM; Rossing P; Ahlers C; Brinker M; Joseph A; Lambelet M; Lawatscheck R; Filippatos GS;
    JAMA Netw Open; 2022 Oct; 5(10):e2236123. PubMed ID: 36287567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
    Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
    Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.
    Cohen S; Sternlicht H; Bakris GL
    Curr Diab Rep; 2022 May; 22(5):213-218. PubMed ID: 35441935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mineralocorticoid receptor antagonists: A new therapeutic option for diabetic kidney disease].
    Girerd S; Soulie M; Barrera-Chimal J; Jaisser F
    Med Sci (Paris); 2023 Apr; 39(4):335-343. PubMed ID: 37094266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
    Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
    Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
    Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease.
    Ortiz A; Ferro CJ; Balafa O; Burnier M; Ekart R; Halimi JM; Kreutz R; Mark PB; Persu A; Rossignol P; Ruilope LM; Schmieder RE; Valdivielso JM; Del Vecchio L; Zoccali C; Mallamaci F; Sarafidis P;
    Nephrol Dial Transplant; 2023 Jan; 38(1):10-25. PubMed ID: 33944938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials.
    Arici M; Altun B; Araz M; Atmaca A; Demir T; Ecder T; Guz G; Gogas Yavuz D; Yildiz A; Yilmaz T
    Front Med (Lausanne); 2024; 11():1384454. PubMed ID: 38947237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
    Kolkhof P; Lawatscheck R; Filippatos G; Bakris GL
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review].
    Salukhov VV; Shamkhalova MS; Duganova AV
    Ter Arkh; 2023 Apr; 95(3):261-273. PubMed ID: 37167149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
    Barrera-Chimal J; Lima-Posada I; Bakris GL; Jaisser F
    Nat Rev Nephrol; 2022 Jan; 18(1):56-70. PubMed ID: 34675379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
    Kintscher U
    Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
    Filippatos G; Anker SD; August P; Coats AJS; Januzzi JL; Mankovsky B; Rossing P; Ruilope LM; Pitt B; Sarafidis P; Teerlink JR; Kapelios CJ; Gebel M; Brinker M; Joseph A; Lage A; Bakris G; Agarwal R
    Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):183-191. PubMed ID: 36639130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease.
    Verma A; Patel AB
    Trends Endocrinol Metab; 2021 May; 32(5):261-263. PubMed ID: 33637415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.